Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 10Terminated 2Recruiting 2

Sponsor Class

OTHER 3NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Recurrence 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Nonhematological Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × sapanisertib × Clear all
NCT05275673 2025-04-24

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Faeth Therapeutics

Phase 2 Terminated
7 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

NCT03370302 2023-02-08

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Calithera Biosciences, Inc

Phase 1 Terminated
28 enrolled 33 charts

Advanced Nonhematological Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡